Abingdon Health Plc (LON:ABDX – Get Rating) shares hit a new 52-week high on Wednesday . The company traded as high as GBX 15.50 ($0.19) and last traded at GBX 15 ($0.19), with a volume of 834857 shares changing hands. The stock had previously closed at GBX 14.20 ($0.18). Abingdon Health Stock Up 5.6 % […]
Shares of Abingdon Health Plc (LON:ABDX – Get Rating) were up 3.1% on Wednesday . The stock traded as high as GBX 8.50 ($0.11) and last traded at GBX 8.25 ($0.10). Approximately 282,891 shares traded hands during trading, a decline of 16% from the average daily volume of 337,218 shares. The stock had previously closed […]
27 April 2021 | 08:52am
StockMarketWire.com - Rapid tests manufacturer Abingdon Health warned on performance after a slower-than-expected uptake of its Covid-19 test kits.
For fiscal 2021, revenue was now expected in the range of £11.4 million to £17.0 million, with an adjusted earnings before interest, taxes, depreciation and amortisation, or EBITDA in the range of -£3.3 million to £0.0 million. The speed of adoption and therefore the receipt of orders is taking longer than the board originally anticipated, the company said. The board therefore expects the results for FY21 will be substantially below the current market expectations, it added.
Story provided by StockMarketWire.com
Share price
10 March 2021 | 14:11pm
StockMarketWire.com - International developer and manufacturer of rapid tests Abingdon Health has signed a non-exclusive sales and distribution agreement in the UK and Europe for the AbC-19 rapid neutralising antibody test with BioSure UK.
Under the terms of the agreement, Abingdon Health and BioSure UK intend to establish a strategic distribution relationship to enable them to identify and maximise opportunities for the sale of the rapid neutralising antibody test in the UK and European territories, prioritising healthcare, workplace and pharmacy settings.
Abingdon Health chief executive Chris Yates said: The nature of SARS-CoV-2 testing is changing. Where antibody tests were once predominantly used for charting the spread of infection within communities, today they are emerging as a key pillar of large-scale immunisation campaigns.